Clinical Data Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis PharmaTimesLead candidate ETD001 delivers significant lung function improvementRespiratoryRead full story pharminent May 12, 2026 (Last updated: May 16, 2026) PharmaTimes Lead candidate ETD001 delivers significant lung function improvement Respiratory Read full story Post navigation Previous: Cellular Intelligence scoops up Novo’s Parkinson’s therapyNext: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026